{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "31825993",
  "DateCompleted": {
    "Year": "2020",
    "Month": "03",
    "Day": "24"
  },
  "DateRevised": {
    "Year": "2020",
    "Month": "03",
    "Day": "24"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2019",
        "Month": "12",
        "Day": "11"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "e0225860",
      "10.1371/journal.pone.0225860"
    ],
    "Journal": {
      "ISSN": "1932-6203",
      "JournalIssue": {
        "Volume": "14",
        "Issue": "12",
        "PubDate": {
          "Year": "2019"
        }
      },
      "Title": "PloS one",
      "ISOAbbreviation": "PLoS One"
    },
    "ArticleTitle": "Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells.",
    "Pagination": {
      "StartPage": "e0225860",
      "MedlinePgn": "e0225860"
    },
    "Abstract": {
      "AbstractText": [
        "Epithelial ovarian cancers are insidious pathologies that give a poor prognosis due to their late discovery and the increasing emergence of chemoresistance. Development of small pharmacological anticancer molecules remains a major challenge. Ribavirin, usually used in the treatment of hepatitis C virus infections and more recently few cancers, has been a suggestion. However, Ribavirin has many side-effects, suggesting that the synthesis of analogs might be more appropriate. We have investigated the effect of a Ribavirin analog, SRO-91, on cancer cell behavioral characteristics considered as some of the hallmarks of cancer. Two human ovarian adenocarcinoma cell lines (SKOV3 and IGROV1) and normal cells (mesothelial and fibroblasts) have been used to compare the effects of SRO-91 with those of Ribavirin on cell behavior underlying tumor cell dissemination. SRO-91, like Ribavirin, inhibits proliferation, migration, clonogenicity and spheroids formation of cancer cells. Unlike Ribavirin, SRO-91 is preferentially toxic to cancer compared with normal cells. An in vitro physiologically relevant model showed that SRO-91, like Ribavirin or cisplatin, inhibits cancer cell implantation onto peritoneal mesothelium. In conclusion, SRO-91 analog effects on tumor dissemination and its safety regarding non-cancerous (normal) cells are encouraging findings a promising drug for the treatment of ovarian cancer."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Equipe de Recherche sur les Relations Matrice Extracellulaire-Cellules, ERRMECe (EA1391), Institut des Mat\u00e9riaux, I-MAT (FD4122), University of Cergy-Pontoise, MIR, rue Descartes, France."
          },
          {
            "Identifier": [],
            "Affiliation": "Normandie University, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment, BioTICLA Axis (Biology and Innovative Therapeutics for Ovarian Cancers), Esplanade de la Paix, Caen, France."
          }
        ],
        "LastName": "Wambecke",
        "ForeName": "Ana\u00efs",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Equipe de Recherche sur les Relations Matrice Extracellulaire-Cellules, ERRMECe (EA1391), Institut des Mat\u00e9riaux, I-MAT (FD4122), University of Cergy-Pontoise, MIR, rue Descartes, France."
          }
        ],
        "LastName": "Laurent-Issartel",
        "ForeName": "Carine",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Equipe de Recherche sur les Relations Matrice Extracellulaire-Cellules, ERRMECe (EA1391), Institut des Mat\u00e9riaux, I-MAT (FD4122), University of Cergy-Pontoise, MIR, rue Descartes, France."
          }
        ],
        "LastName": "Leroy-Dudal",
        "ForeName": "Johanne",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Normandie University, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment, BioTICLA Axis (Biology and Innovative Therapeutics for Ovarian Cancers), Esplanade de la Paix, Caen, France."
          }
        ],
        "LastName": "Giffard",
        "ForeName": "Florence",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratoire de Chimie Biologique, University of Cergy-Pontoise, mail Gay-Lussac, Cergy-pontoise, France."
          }
        ],
        "LastName": "Cosson",
        "ForeName": "Fanny",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratoire de Chimie Biologique, University of Cergy-Pontoise, mail Gay-Lussac, Cergy-pontoise, France."
          }
        ],
        "LastName": "Lubin-Germain",
        "ForeName": "Nad\u00e8ge",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratoire de Chimie Biologique, University of Cergy-Pontoise, mail Gay-Lussac, Cergy-pontoise, France."
          }
        ],
        "LastName": "Uziel",
        "ForeName": "Jacques",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Equipe de Recherche sur les Relations Matrice Extracellulaire-Cellules, ERRMECe (EA1391), Institut des Mat\u00e9riaux, I-MAT (FD4122), University of Cergy-Pontoise, MIR, rue Descartes, France."
          }
        ],
        "LastName": "Kellouche",
        "ForeName": "Sabrina",
        "Initials": "S"
      },
      {
        "Identifier": [
          "0000-0001-8765-7280"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Equipe de Recherche sur les Relations Matrice Extracellulaire-Cellules, ERRMECe (EA1391), Institut des Mat\u00e9riaux, I-MAT (FD4122), University of Cergy-Pontoise, MIR, rue Descartes, France."
          }
        ],
        "LastName": "Carreiras",
        "ForeName": "Franck",
        "Initials": "F"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "PLoS One",
    "NlmUniqueID": "101285081",
    "ISSNLinking": "1932-6203"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "49717AWG6K",
      "NameOfSubstance": "Ribavirin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Cell Line, Tumor"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Cell Movement"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Cell Proliferation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Screening Assays, Antitumor"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug therapy",
        "metabolism",
        "pathology"
      ],
      "DescriptorName": "Ovarian Neoplasms"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Ribavirin"
    }
  ],
  "CoiStatement": "The authors have declared that no competing interests exist."
}